Texas Bank & Trust Co Sells 1,080 Shares of Johnson & Johnson $JNJ

Texas Bank & Trust Co lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.2% in the first quarter, HoldingsChannel.com reports. The firm owned 19,696 shares of the company’s stock after selling 1,080 shares during the quarter. Johnson & Johnson accounts for approximately 1.4% of Texas Bank & Trust Co’s portfolio, making the stock its 18th biggest holding. Texas Bank & Trust Co’s holdings in Johnson & Johnson were worth $3,266,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Highline Wealth Partners LLC increased its position in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares during the period. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $47,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $49,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $52,000. Finally, Capital A Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $50,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Barclays raised their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Citigroup lifted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday, August 21st. Leerink Partners downgraded shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Finally, UBS Group lifted their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $176.29.

Johnson & Johnson Price Performance

JNJ opened at $177.10 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market capitalization of $426.52 billion, a price-to-earnings ratio of 18.94, a P/E/G ratio of 2.23 and a beta of 0.41. The firm’s fifty day moving average price is $165.99 and its two-hundred day moving average price is $160.01. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s payout ratio is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.